Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Multinational, Double-Blind, Placebo-Controlled, Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Interferon-beta in Subjects With Multiple Sclerosis.

NCT00489489 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00489489
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00489489 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Multinational, Double-Blind, Placebo-Controlled, Parallel-Group Design Pilot Study to Estimate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamic Effects of Teriflunomide for 24 Weeks When Added to Treatment With Interferon-beta in Subjects With Multiple Sclerosis.
Lead sponsor
Sanofi
Phase
Phase 2
Overall status
Completed
Start date
May 31, 2007
Completion date
June 30, 2009
Enrollment
118 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

multiple sclerosis